secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0000950170-25-064432
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytokinetics Q1 net loss $161.4M; aficamten PDUFA extended to Dec 26, 2025
--------------------------------------------------------------------------

- Net loss $161.4M ($1.36/share) vs $135.6M ($1.33/share) in Q1 2024; revenue $1.6M.
- FDA extended aficamten PDUFA date for obstructive HCM to Dec 26, 2025 due to REMS submission; no additional clinical data requested.
- MAPLE-HCM topline results expected May 2025; ACACIA-HCM enrollment completed, topline 1H 2026.
- Cash, cash equivalents, and investments ~$1.1B at Mar 31, down $132.2M from Dec 31, 2024.
- Full-year 2025 GAAP operating expense guidance maintained at $670-710M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000095017025064432/0000950170-25-064432-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000095017025064432/cytk-20250506.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-064432

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer